Clinical trials: Relapsed/ Refractory T-cell Malignancies
Lymphoblastic Leukemia, Acute, Lymphoblastic Leukemia, Acute, Childhood
EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)
An experimental drug called EZN-3042 targets survivin, a protein expressed in leukemia cells at relapse that promotes the leukemia cells to grow.
- Conditions
- Lymphoblastic Leukemia, Acute, Lymphoblastic Leukemia, Acute, Childhood, Leukemia, Lymphoblastic, Acute, T Cell, Leukemia, Lymphoblastic, Acute
- Trial name
- NCT01186328
- Testing
- EZN-3042, Cytarabine, Doxorubicin
- Where
- 7 sites in United States, Australia
- Volunteers
- 6 people
- Sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma
RATIONALE: Giving high doses of chemotherapy drugs, such as busulfan and cyclophosphamide, before a donor bone marrow transplant helps stop the growth of cancer cells.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Monoblastic Leukemia (M5a)
- Trial name
- NCT01177371
- Testing
- busulfan, cyclophosphamide, allogeneic bone marrow transplantation
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Case Comprehensive Cancer Center
Acute T Lymphpblastic Leukemia/Lymphoma
VHAG in Treating R/R T-ALL/LBL
Acute T cell lymphoblastic leukemia/lymphoma (T-ALL/LBL) is an aggressive type of leukemia that results from the malignant evolution of T-lineage progenitor cells at different differentiation stages.
- Trial name
- NCT06742463
- Testing
- Venetoclax, homoharringtonine, Cytarabine (Ara-C)
- Where
- China
- Volunteers
- 50 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia
A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia
The purpose of this study is to find out whether CD371-YSNVZ-IL18 CAR T cells are safe, and to look for the highest dose of CD371-YSNVZ-IL18 CAR T cells that cause few or mild side effects in participants.
- Conditions
- Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse
- Trial name
- NCT06017258
- Testing
- CD371-specific/YSNVz/I-18 CAR T cells
- Where
- 7 sites in United States
- Volunteers
- 15 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Relapsed/Refractory Peripheral T Cell Lymphoma
A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
This is a randomized, double-blind, multi-center, phase III clinical trial designed to evaluate the efficacy of XNW5004 tablets versus Chidamide in Relapsed/Refractory PTCL, with a target of enrolling 120 subjects.
- Trial name
- NCT06776952
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Evopoint Biosciences Inc.
B-cell Acute Lymphoblastic Leukemia
Allogeneic Second-generation CD19-CAR T Cells for Pediatric Relapsed/Refractory B-ALL
This is a phase I, open label study to evaluate the safety, identify the recommended dose (RD) and obtain preliminar evidence of the efficacy of allogeneic, CD19-directed Chimeric Antigen Receptor T (alloCAR-T) cells in pediatric…
- Trial name
- NCT06080191
- Testing
- CD19-CAR_Lenti_ALLO
- Where
- Italy
- Volunteers
- 24 people
- Sponsor
- Bambino Gesù Hospital and Research Institute
NK/T-Cell Lymphoma
A Clinical Trial of Chidamide Combined With Etoposide in Relapsed or Refractory NK/T-cell Lymphoma
To observe the safety, tolerability and clinical effects of Chidamide Combined With Etoposide in Relapsed or Refractory NK/T-cell Lymphoma.
- Trial name
- NCT04490590
- Testing
- Chidamide+ Etoposide
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Mingzhi Zhang
Relapsed Neuroblastoma, Refractory Neuroblastoma
C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)
This study is for patients with neuroblastoma, sarcoma, uveal melanoma, breast cancer, or another cancer that expresses a substance on the cancer cells called GD2.
- Conditions
- Relapsed Neuroblastoma, Refractory Neuroblastoma, Relapsed Osteosarcoma, Relapsed Ewing Sarcoma
- Trial name
- NCT03635632
- Testing
- C7R-GD2.CART cells
- Where
- 2 sites in United States
- Volunteers
- 94 people
- Sponsor
- Baylor College of Medicine
B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma
Efficacy and Safety of PZ01 Treatment in Patients With r/r CD19+ B-cell Acute Lymphoblastic Leukemia/B Cell Lymphoma
The major aim of this research is to assess the feasibility, safety and effectiveness of CD19 CAR-T Cell Therapy for Relapsed/ Refractory Acute Lymphoblastic Leukemia/ B cell Lymphoma patients who have applied it.
- Trial name
- NCT03281551
- Testing
- PZ01 CAR-T cells
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Pinze Lifetechnology Co. Ltd.
T Lymphoblastic Leukemia/Lymphoma, T-cell Acute Lymphoblastic Leukemia
Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies
The purpose of this study is to evaluate the safety and efficacy of CAR T cell treatment targeting CD7 in patients with relapsed or refractory CD7 positive T-cell hematological maliganacies
- Conditions
- T Lymphoblastic Leukemia/Lymphoma, T-cell Acute Lymphoblastic Leukemia, Peripheral T Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma
- Trial name
- NCT05290155
- Testing
- anti-CD7 CAR-T cells
- Where
- China
- Volunteers
- 14 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Acute Lymphoblastic Leukemia, in Relapse, Non-Hodgkin's Lymphoma, Relapsed
Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL
This pilot study examines the safety and efficacy of anti-CD19 CAR T cells manufactured on-site in children and young adults with relapsed or refractory CD19+ B cell acute lymphoblastic leukemia or CD19+ B cell non Hodgkin…
- Conditions
- Acute Lymphoblastic Leukemia, in Relapse, Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory, Acute Lymphoblastic Leukemia With Failed Remission
- Trial name
- NCT05779930
- Testing
- CD19 specific Chimeric Antigen Receptor T Cell
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Nationwide Children's Hospital
Leukemia, Lymphoblastic, Acute, T-cell, Myelogenous Leukemia
A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute Lymphoblastic Leukemia/Lymphoma (ALL)(0752-013)
A Notch signalling pathway inhibitor study in pediatric and adult patients with relapsed (worsening) or refractory (not responding to treatment) T-cell acute lymphoblastic leukemia/lymphoma (T-ALL).
- Conditions
- Leukemia, Lymphoblastic, Acute, T-cell, Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT00100152
- Testing
- MK0752, (Notch Inhibitor)
- Volunteers
- 50 people
- Sponsor
- Merck Sharp & Dohme LLC
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma
A phase 2 study of venetoclax in combination with isatuximab and dexamethasone for relapsed/refractory multiple myeloma patients with t(11;14)
- Trial name
- NCT06115135
- Testing
- Venetoclax
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- Oncotherapeutics
Cancer
Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation
RATIONALE: Antivirals such as ribavirin are used to treat infections caused by viruses. It is not yet known if ribavirin is more effective with or without monoclonal antibody therapy in treating patients who develop RSV pneumonia…
- Trial name
- NCT00014391
- Testing
- palivizumab, ribavirin
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Leukemia, Lymphoma
Cyclophosphamide Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy or…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00006042
- Testing
- filgrastim, cyclophosphamide, fludarabine phosphate
- Where
- United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
T-cell Lymphoma, T-cell Leukemia
CD4CAR for CD4+ Leukemia and Lymphoma
This study is designed as a single arm open label Phase I, 3x3, multicenter study of CD4-directed chimeric antigen receptor engineered T-cells (CD4CAR) in patients with relapsed or refractory T-cell leukemia and lymphoma.
- Trial name
- NCT03829540
- Testing
- CD4CAR
- Where
- 6 sites in United States
- Volunteers
- 20 people
- Sponsor
- Huda Salman
Acute Myeloid Leukemia, Acute Lymphoblastic T-cell Leukemia
Feasibility and Safety of Donor-derived NK-cell Infusions for Leukemia Relapse Prophylaxis After Hematopoietic Stem Cell Transplantation
This pilot clinical trial aims to evaluate the feasibility, adverse reactions and maximum tolerated dose of mbIL21 ex vivo-expanded donor-derived NK-cell infusions before and after haploidentical or matched-related hematopoietic…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic T-cell Leukemia, Mixed Phenotype Acute Leukemia
- Trial name
- NCT07256210
- Testing
- Donor-derived Natural Killer Cell
- Where
- Russia
- Volunteers
- 15 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
NonHodgkin Lymphoma, Lymphoproliferative Disorders
Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE)
Subjects have a type of a lymph node cancer called Non-Hodgkin's Lymphoma (NHL) or lymphoproliferative disease (LPD), which affects their immunity, blood production, and can involve multiple other organs in the body.
- Conditions
- NonHodgkin Lymphoma, Lymphoproliferative Disorders, EBV Related Lymphoma, EBV-Related PTLD
- Trial name
- PREVALE (NCT02973113)
- Testing
- EBVST Cells, Nivolumab
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Baylor College of Medicine
Relapse Leukemia, Refractory Leukemia
Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
CD19 CAR-T has been widely developed in patients with R/R ALL and has also been generally recognized by the industry. In 2017, the U.S. FDA approved Novartis's CD 19 CAR-T product Kymriah for the treatment of R/R ALL.
- Trial name
- CAR-T (NCT05164042)
- Testing
- Allogeneic CD19 CAR-T cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shenzhen University General Hospital
B-cell Acute Lymphoblastic Leukemia
Dose Escalation Study of UCART19 in Adult Patients With Relapsed / Refractory B-cell Acute Lymphoblastic Leukaemia
The study is in two parts: a dose escalation then a safety dose expansion. The purpose of the dose escalation part is to evaluate the safety and tolerability of ascending doses of UCART19 (dose-escalation part) given as a single…
- Trial name
- CALM (NCT02746952)
- Testing
- UCART19
- Where
- 9 sites in United States, France and 2 more
- Volunteers
- 25 people
- Sponsor
- Institut de Recherches Internationales Servier